Zacks Investment Research downgraded shares of Nu Skin Enterprises, Inc. (NYSE:NUS) from a hold rating to a sell rating in a research report report published on Tuesday.
According to Zacks, “Nu Skin is a premier anti-aging company. The company’s anti-aging products feature the ageLOC line of products including ageLOC Tru Face Essence Ultra firming serum, the ageLOC TR90 weight management and body shaping system, ageLOC R2 nutritional supplement, and ageLOC Transformation daily skin care system. “
Other equities research analysts have also issued reports about the company. TheStreet upgraded Nu Skin Enterprises from a c+ rating to a b rating in a research note on Wednesday, August 2nd. Pivotal Research restated a buy rating and set a $80.00 price target (up from $65.00) on shares of Nu Skin Enterprises in a research note on Thursday, June 22nd. Deutsche Bank AG upped their price target on Nu Skin Enterprises from $63.00 to $66.00 and gave the stock a buy rating in a research note on Wednesday, June 21st. BidaskClub lowered Nu Skin Enterprises from a strong-buy rating to a buy rating in a research note on Monday, July 31st. Finally, Stifel Nicolaus set a $50.00 price target on Nu Skin Enterprises and gave the stock a sell rating in a research note on Thursday, August 3rd. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $62.00.
Nu Skin Enterprises (NYSE:NUS) traded up 0.44% during trading on Tuesday, reaching $63.88. The company’s stock had a trading volume of 39,975 shares. Nu Skin Enterprises has a 1-year low of $46.35 and a 1-year high of $65.85. The company has a market capitalization of $3.38 billion, a P/E ratio of 21.36 and a beta of 1.40. The company’s 50-day moving average is $61.77 and its 200-day moving average is $59.36.
Nu Skin Enterprises (NYSE:NUS) last released its earnings results on Wednesday, August 2nd. The company reported $0.77 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.69 by $0.08. Nu Skin Enterprises had a return on equity of 24.14% and a net margin of 7.53%. The firm had revenue of $550.10 million for the quarter, compared to the consensus estimate of $548.09 million. During the same period in the prior year, the business posted $0.79 earnings per share. The firm’s revenue for the quarter was down 8.4% compared to the same quarter last year. Equities analysts anticipate that Nu Skin Enterprises will post $3.22 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/10/18/nu-skin-enterprises-inc-nus-lowered-to-sell-at-zacks-investment-research.html.
In other news, President Ryan S. Napierski sold 6,933 shares of the stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $64.00, for a total value of $443,712.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Ryan S. Napierski sold 8,000 shares of the stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $65.00, for a total value of $520,000.00. Following the completion of the sale, the president now owns 68,170 shares of the company’s stock, valued at approximately $4,431,050. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,040 shares of company stock valued at $1,708,157. Insiders own 5.20% of the company’s stock.
Several hedge funds have recently bought and sold shares of NUS. BlackRock Inc. grew its stake in shares of Nu Skin Enterprises by 21,593.4% in the first quarter. BlackRock Inc. now owns 6,683,531 shares of the company’s stock valued at $371,201,000 after buying an additional 6,652,722 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Nu Skin Enterprises by 11.8% in the first quarter. Vanguard Group Inc. now owns 6,011,632 shares of the company’s stock valued at $333,887,000 after buying an additional 634,951 shares in the last quarter. State Street Corp grew its stake in shares of Nu Skin Enterprises by 76.7% in the first quarter. State Street Corp now owns 1,416,873 shares of the company’s stock valued at $78,695,000 after buying an additional 614,817 shares in the last quarter. UBS Asset Management Americas Inc. grew its stake in shares of Nu Skin Enterprises by 751.6% in the second quarter. UBS Asset Management Americas Inc. now owns 309,983 shares of the company’s stock valued at $19,479,000 after buying an additional 273,581 shares in the last quarter. Finally, Principal Financial Group Inc. grew its stake in shares of Nu Skin Enterprises by 84.7% in the second quarter. Principal Financial Group Inc. now owns 420,755 shares of the company’s stock valued at $26,440,000 after buying an additional 192,958 shares in the last quarter. Institutional investors and hedge funds own 79.24% of the company’s stock.
About Nu Skin Enterprises
Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system.
Receive News & Ratings for Nu Skin Enterprises Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises Inc. and related companies with MarketBeat.com's FREE daily email newsletter.